Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a predilection for the genital region. Genital HS requires medical and surgical management as well as close collaboration among a multidisciplinary team.
Hidradenitis suppurativa is a disease of the hair follicles that results in recurrent nodules, abscesses, and tunneling sinus tracts. Medical treatment mainstays include antibiotics and retinoids, but the evolving class of biologic medications has gained traction in the treatment of moderate and severe disease. Many of the medical therapies come with adverse effects requiring clinical and laboratory monitoring over the course of treatment. When lesions are refractory to therapy or are too large for medical therapy alone, surgical intervention is required. Surgical procedures can include treatment of affected areas with deroofing or excision of affected skin. When large portions of genital skin are removed, reconstruction is necessary to restore function and aesthetics of the genitals. We describe a variety of reconstructive techniques based on the size and location of the skin deficiency.
Conclusions and Relevance
Effective management of genital hidradenitis suppurativa requires a thorough understanding of medical and surgical techniques for prevention, treatment, and reconstruction of genital defects.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Bradley D. Figler, MD, Department of Urology, University of North Carolina at Chapel Hill, 170 Manning Dr, 2113 Physicians Office Bldg, Chapel Hill, NC 27599 (email@example.com).
Published Online: August 19, 2020. doi:10.1001/jamasurg.2020.2611
Accepted for Publication: March 21, 2020.
Conflict of Interest Disclosures: Dr Sayed reports the following disclosures: AbbVie (speaker, investigator, and consulting), Novartis (speaker and investigator), InflaRx (investigator), and UCB (investigator and advisory board). No other disclosures were reported.
You currently have no searches saved.
You currently have no courses saved.